Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DITROPAN XL vs DETROL LA in Overactive Bladder
NCT00293839Phase 3Completed
- Sponsor
- ALZA Corporation
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of oxybutynin in overactive bladder (OAB) (2 arms), sponsored by ALZA Corporation. Primary endpoint: Number of weekly urge urinary incontinence (Urge-UI) episodes at 12 weeks. Status: completed.
02
Drugs
oxybutynin
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00293839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00293839.